Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 651

Sort by

Sort Order Select

Journal Articles

TP53 Mutations within T Cells Induce T-Cell Exhaustion and Functional Impairment in TP53 Mutant AML

Li Li, Muharrem Muftuoglu, Edward Ayoub, Aram Bidikian, Prashant Menon, Jiangxing Lv, Mahesh Basyal, Andrea Bedoy, Anudishi Tyagi, Amanda Eckstrom, Venkata Lokesh Battula, Navin Varadarajan, Ghayas C. Issa, Michael Andreeff

Blood (2024) 144 (Supplement 1): 330.

https://doi.org/10.1182/blood-2024-210412

Published: 2024

Journal Articles

Novel p53 Mutant Mouse Model Recapitulates the Biology of Human Therapy-Related Myeloid Neoplasms

Rasoul Pourebrahim, Dexin Yang, Priyanka Khanna, Muharrem Muftuoglu, Lauren B. Ostermann, Shayaun Khazaei, Ran Zhao, Mihai Gagea, Simona Colla, Guillermo Garcia-Manero, Ruoyan Li, Michael Andreeff, Koichi Takahashi

Blood (2024) 144 (Supplement 1): 882.

https://doi.org/10.1182/blood-2024-207582

Published: 2024

Journal Articles

Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse

Blood (2024) 144 (Supplement 1): 735.

https://doi.org/10.1182/blood-2024-203706

Published: 2024

Journal Articles

Mitigating Therapy-Related Myeloid Neoplasia in p53-Mutant Clones through Targeted DNA Repair Pathway Inhibition with PARP Inhibitors

Rasoul Pourebrahim, Priyanka Khanna, Dexin Yang, Muharrem Muftuoglu, Lauren B. Ostermann, Shayaun Khazaei, Ran Zhao, Amma Asare, Richard A. Hajek, Sanghoon Lee, Sara Corvingo, Mihai Gagea, Anil Sood, Ruoyan Li, Koichi Takahashi, Michael Andreeff

Blood (2024) 144 (Supplement 1): 726.

https://doi.org/10.1182/blood-2024-208373

Published: 2024

Journal Articles

Targeting Lipid Droplet Biogenesis to Enhance Ferroptosis in Acute Myeloid Leukemia

Liang Zhang, Ran Zhao, Hiroki Akiyama, Jalen Nguyen, Kazuharu Kamachi, Saurabh Kumar Gupta, Valeria Impedovo, G. Lavender Hackman, Michael Andreeff, Alessia Lodi, Jo Ishizawa

Blood (2024) 144 (Supplement 1): 1400.

https://doi.org/10.1182/blood-2024-208616

Published: 2024

Journal Articles

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome

Blood (2024) 144 (Supplement 1): 3212.

https://doi.org/10.1182/blood-2024-205186

Published: 2024

Journal Articles

Decitabine-Venetoclax Treatment Reactivates Endogenous Retrovirus RNA Signaling in AML Cells and Induces T Cell Activation

Kotoko Yamatani, Kaori Saito, Abhishek Maiti, Abdullah Khasawneh, Faith Jessica Paran, Tastuya Suzuki, Toru Okamoto, Kala Hayes, Zhihong Zeng, Courtney D. DiNardo, Michael Andreeff, Marina Konopleva, Yoko Tabe

Blood (2024) 144 (Supplement 1): 1389.

https://doi.org/10.1182/blood-2024-202722

Published: 2024

Journal Articles

Spatial Analysis of Human p53 Mutated AML Bone Marrow Reveals Novel MRD Clusters and Spatial Microenvironmental Features of p53 Mutated AML

Hideaki Mizuno, Yuki Nishida, Edward Ayoub, Akshay Basi, Andrea Bedoy, Javier A. Gomez, Jared K. Burks, Rashmi Kanagal-Shamanna, Michael Andreeff

Blood (2024) 144 (Supplement 1): 1301.

https://doi.org/10.1182/blood-2024-209852

Published: 2024

Journal Articles

Single-Cell Multiomics Unveils Venetoclax-Resistant Monocytic Differentiation and Immune Evasion in TP53 Mutant AML Clones

Edward Ayoub, David Lehotzky, Li Li, Muharrem Muftuoglu, Yuki Nishida, Vakul Mohanty, Jake S Leighton, Tallie Patsilevas, Mahesh Basyal, Andrea Bedoy, Torsten Haferlach, Koichi Takahashi, Ken Chen, Nicholas Navin, Ghayas C. Issa, Gad Getz, Michael Andreeff

Blood (2024) 144 (Supplement 1): 61.

https://doi.org/10.1182/blood-2024-211845

Published: 2024

Journal Articles

Failure to Execute Caspase Activation Drives Therapy Resistance in TP53 Mutated AML

Blood (2024) 144 (Supplement 1): 53.

https://doi.org/10.1182/blood-2024-211997

Published: 2024

Journal Articles

Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML

Blood (2024) 144 (Supplement 1): 216.

https://doi.org/10.1182/blood-2024-204375

Published: 2024

Journal Articles

A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)

Blood (2024) 144 (Supplement 1): 4265.2.

https://doi.org/10.1182/blood-2024-201582

Published: 2024

Journal Articles

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome

Blood (2024) 144 (Supplement 1): 4601.

https://doi.org/10.1182/blood-2024-204040

Published: 2024

Journal Articles

Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3 -Tyrosine Kinase Domain (TKD) Mutations

Blood (2024) 144 (Supplement 1): 841.

https://doi.org/10.1182/blood-2024-204042

Published: 2024

Journal Articles

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Blood (2024) 144 (Supplement 1): 4263.

https://doi.org/10.1182/blood-2024-204296

Published: 2024

Journal Articles

Reactivation of p53 in TP53 -Y220C Mutant AML: Mechanism of Action and Mechanism-Based Drug Combinations

Bing Z. Carter, Po Yee Mak, Baozhen Ke, Xiaogang Wu, Steffen Boettcher, Lauren B. Ostermann, Andrea Bedoy, Georgina Gener-Ricos, Jayastu Senapati, Courtney D. DiNardo, Anna Puzio-Kuter, Arnold Levine, Michael Andreeff

Blood (2024) 144 (Supplement 1): 4155.

https://doi.org/10.1182/blood-2024-208403

Published: 2024

Journal Articles

Phase 1 Study of AXL/MER/CSF1R Inhibitor Q702 with Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Abhishek Maiti, Sean M. Post, Courtney D. DiNardo, Naval Daver, Tapan M. Kadia, Allison Pike, Hyunsoo Hwang, Xuelin Huang, Michael Andreeff, Farhad Ravandi, Jinho CHOI, Hyunji Ahn, Jeongjun Kim, Kiyean Nam, Gautam Borthakur

Blood (2024) 144 (Supplement 1): 5994.

https://doi.org/10.1182/blood-2024-202834

Published: 2024

Journal Articles

Annamycin, a Non-Cardiotoxic Anthracycline Demonstrates Unique Organotropism and Activity Against Ara-C and Venetoclax Resistant AML

Rafal Jerzy Zielinski, Krzysztof Grela, Roberto Cardenas-Zuniga, Stanislaw Skora, Izabela Fokt, Mihai Gagea, Michael Andreeff, Natalia Baran, Waldemar Priebe

Blood (2024) 144 (Supplement 1): 5796.

https://doi.org/10.1182/blood-2024-206164

Published: 2024

Journal Articles

“Guided” Unsupervised Multiplexed Cytof Analysis Enhances Detection of Minimal/Measurable Residual Disease in Acute Myeloid Leukemia

Muharrem Muftuoglu, Li Li, Mahesh Basyal, Jiangxing Lv, Yukun Tan, Ken Chen, Michael Andreeff

Blood (2024) 144 (Supplement 1): 6178.

https://doi.org/10.1182/blood-2024-212260

Published: 2024

Journal Articles

Isolation of Lipid Droplets from Acute Myeloid Leukemia Cells for Lipidomic Analysis

Ran Zhao, Liang Zhang, Kazuharu Kamachi, Saurabh Kumar Gupta, Hiroki Akiyama, Jalen Nguyen, Michael Andreeff, Jo Ishizawa, Alessia Lodi

Blood (2024) 144 (Supplement 1): 7502.

https://doi.org/10.1182/blood-2024-201676

Published: 2024

NARROW

TP53 Mutations within T Cells Induce T-Cell Exhaustion and Functional Impairment in TP53 Mutant AML

Novel p53 Mutant Mouse Model Recapitulates the Biology of Human Therapy-Related Myeloid Neoplasms

Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse

Mitigating Therapy-Related Myeloid Neoplasia in p53-Mutant Clones through Targeted DNA Repair Pathway Inhibition with PARP Inhibitors

Targeting Lipid Droplet Biogenesis to Enhance Ferroptosis in Acute Myeloid Leukemia

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome

Decitabine-Venetoclax Treatment Reactivates Endogenous Retrovirus RNA Signaling in AML Cells and Induces T Cell Activation

Spatial Analysis of Human p53 Mutated AML Bone Marrow Reveals Novel MRD Clusters and Spatial Microenvironmental Features of p53 Mutated AML

Single-Cell Multiomics Unveils Venetoclax-Resistant Monocytic Differentiation and Immune Evasion in TP53 Mutant AML Clones

Failure to Execute Caspase Activation Drives Therapy Resistance in TP53 Mutated AML

Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML

A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome

Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3 -Tyrosine Kinase Domain (TKD) Mutations

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Reactivation of p53 in TP53 -Y220C Mutant AML: Mechanism of Action and Mechanism-Based Drug Combinations

Phase 1 Study of AXL/MER/CSF1R Inhibitor Q702 with Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Annamycin, a Non-Cardiotoxic Anthracycline Demonstrates Unique Organotropism and Activity Against Ara-C and Venetoclax Resistant AML

“Guided” Unsupervised Multiplexed Cytof Analysis Enhances Detection of Minimal/Measurable Residual Disease in Acute Myeloid Leukemia

Isolation of Lipid Droplets from Acute Myeloid Leukemia Cells for Lipidomic Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only